The effects of etomidate on expression of high mobility group box 1 via the nuclear factor kappa B pathway in rat model of sepsis

References

• Taeb AM, Hooper MH, Marik PE. Sepsis: current definition, pathophysiology, diagnosis, and management. Nutr Clin Pract. 2017;321296–10. 10.1177/0884533617695243
   PubMedGoogle Scholar
• Aboyoussef AM, Mohammad MK, Abo-Saif AA, et al. Granisetron attenuates liver injury and inflammation in a rat model of cecal ligation and puncture-induced sepsis. J Pharmacol Sci. 2021;147(4):358–366.
   PubMed Web of Science ®Google Scholar
• Stevens NE, Chapman MJ, Fraser CK, et al. Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes. Sci Rep. 2017;7(1):5850.
   PubMedGoogle Scholar
• van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis. 2008;11(1):91–99.
   PubMed Web of Science ®Google Scholar
• Huang W, Tang Y, Li L. HMGB1, a potent proinflammatory cytokine in sepsis. Cytokine. 2010;51(2):119–126.
   PubMed Web of Science ®Google Scholar
• Gibot S, Massin F, Cravoisy A, et al. High-mobility group box 1 protein plasma concentrations during septic shock. Intensive care Med. 2007;33(8):1347–1353.
   PubMed Web of Science ®Google Scholar
• Hou LC, Qin MZ, Zheng LN, et al. Severity of sepsis is correlated with the elevation of serum high-mobility group box 1 in rats. Chin Med J (Engl). 2009;122(4):449–454. (PMID: 19302753).
   PubMed Web of Science ®Google Scholar
• Wang H, Ward MF, Sama AE. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock. 2009;32(4):348–357.
   PubMed Web of Science ®Google Scholar
• Forman SA. Clinical and molecular pharmacology of etomidate. Anesthesiology. 2011;114(3):695–707.
   PubMed Web of Science ®Google Scholar
• Gagnon DJ, Seder DB. Etomidate in sepsis: understanding the dilemma. J Thorac Dis. 2015;7(10):1699–1701.
   PubMed Web of Science ®Google Scholar
• Park HY, Lee Y, Lim CY, et al. Effects of etomidate use in ICU patients on ventilator therapy: a study of 12,526 patients in an open database from a single center. Korean J Anesthesiol. 2021;74(4):300–307.
   PubMed Web of Science ®Google Scholar
• Gu WJ, Wang F, Tang L, et al. Single-dose etomidate does not increase mortality in patients with sepsis: a systematic review and meta-analysis of randomized controlled trials and observational studies. Chest. 2015;147(2):335–346.
   PubMed Web of Science ®Google Scholar
• McPhee LC, Badawi O, Fraser GL, et al. Single-dose etomidate is not associated with increased mortality in ICU patients with sepsis: analysis of a large electronic ICU database. Crit Care Med. 2013;41(3):774–783.
   PubMed Web of Science ®Google Scholar
• Jia L, Hao H, Wang C, et al. Etomidate attenuates hyperoxia-induced acute lung injury in mice by modulating the Nrf2/HO-1 signaling pathway. Exp Ther Med. 2021;22(1):785.
   PubMed Web of Science ®Google Scholar
• Liu M, Zhang Y, Xiong JY, et al. Etomidate mitigates lipopolysaccharide-induced CD14 and TREM-1 expression, NF-kappaB activation, and pro-inflammatory cytokine production in rat macrophages. Inflammation. 2016;39(1):327–335.
   PubMed Web of Science ®Google Scholar
• Dejager L, Pinheiro I, Dejonckheere E, et al. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? Trends Microbiol. 2011;19(4):198–208.
   PubMed Web of Science ®Google Scholar
• Gibson-Corley KN, Olivier AK, Meyerholz DK. Principles for valid histopathologic scoring in research. Vet Pathol. 2013;50(6):1007–1015.
   PubMed Web of Science ®Google Scholar
• Lv S, Han M, Yi R, et al. Anti-TNF-α therapy for patients with sepsis: a systematic meta-analysis. Int J Clin Pract. 2014;68(4):520–528.
   PubMed Web of Science ®Google Scholar
• Opal SM, Fisher CJ Jr., Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The interleukin-1 receptor antagonist sepsis investigator group. Crit Care Med. 1997;25(7):1115–1124.
   PubMed Web of Science ®Google Scholar
• Steinhauser ML, Hogaboam CM, Kunkel SL, et al. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol. 1999;162(1):392–399. PMID: 9886412.
   PubMed Web of Science ®Google Scholar
• Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med. 2004;255(3):320–331.
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418(6894):191–195.
   PubMed Web of Science ®Google Scholar
• Erlandsson Harris H, Andersson U. Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol. 2004;34(6):1503–1512.
   PubMed Web of Science ®Google Scholar
• Karlsson S, Pettila V, Tenhunen J, et al. HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive care Med. 2008;34(6):1046–1053.
   PubMed Web of Science ®Google Scholar
• Wang HL, Xing YQ, Xu YX, et al. The protective effect of lidocaine on septic rats via the inhibition of high mobility group box 1 expression and NF-kappaB activation. Mediators Inflamm. 2013;2013:570370.
   PubMed Web of Science ®Google Scholar
• Bao HG, Li S. Effects of propofol on the outcomes of rats with sepsis. J Surg Res. 2011;168(1):e111–115.
   PubMed Web of Science ®Google Scholar
• Sun H, Hu H, Xu X, et al. Protective effect of dexmedetomidine in cecal ligation perforation-induced acute lung injury through HMGB1/RAGE pathway regulation and pyroptosis activation. Bioengineered. 2021;12(2):10608–10623.
   PubMed Web of Science ®Google Scholar
• Li K, Yang J, Han X. Ketamine attenuates sepsis-induced acute lung injury via regulation of HMGB1-RAGE pathways. Int Immunopharmacol. 2016;34:114–128.
   PubMed Web of Science ®Google Scholar
• Chan CM, Mitchell AL, Shorr AF. Etomidate is associated with mortality and adrenal insufficiency in sepsis: a meta-analysis*. Crit Care Med. 2012;40(11):2945–2953.
   PubMed Web of Science ®Google Scholar
• Matchett G, Gasanova I, Riccio CA, et al. Etomidate versus ketamine for emergency endotracheal intubation: a randomized clinical trial. Intensive care Med. 2022;48(1):78–91.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li RM, Wang C, et al. Etomidate inhibits nuclear factor-kappaB through decreased expression of glucocorticoid receptor in septic rats. Mol Med Rep. 2016;14(6):5760–5766.
   PubMed Web of Science ®Google Scholar
• Li R, Fan L, Ma F, et al. Effect of etomidate on the oxidative stress response and levels of inflammatory factors from ischemia-reperfusion injury after tibial fracture surgery. Exp Ther Med. 2017;13(3):971–975.
   PubMed Web of Science ®Google Scholar
• Wang C, Liu N, Li RM, et al. Effects of propofol and etomidate pretreatment on glucocorticoid receptor expression following induction of sepsis in rats. Genet Mol Res. 2015;14(2):4740–4748.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li R, Zhu J, et al. Etomidate increases mortality in septic rats through inhibition of nuclear factor kappa-B rather than by causing adrenal insufficiency. J Surg Res. 2015;193(1):399–406.
   PubMed Web of Science ®Google Scholar
• Ge Y, Hu S, Zhang Y, et al. Levobupivacaine inhibits lipopolysaccharide-induced high mobility group box 1 release in vitro and in vivo. J Surg Res. 2014;192(2):582–591.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang L, Zhou C, et al. Ketamine inhibits LPS-induced HGMB1 release in vitro and in vivo. Int Immunopharmacol. 2014;23(1):14–26.
   PubMed Web of Science ®Google Scholar
• Besnier E, Clavier T, Tonon MC, et al. Ketamine and etomidate down-regulate the hypothalamic-pituitary-adrenal axis in an endotoxemic mouse model. Anesthesiology. 2017;127(2):347–354.
   PubMed Web of Science ®Google Scholar